A randomized trial comparing intensified CNOP vs. CHOP in patients with aggressive non-Hodgkin's lymphoma

Leukemia and Lymphoma

Volumn 44, Issue 4, 2003, Pages 635-644

  Pangalis, Gerassimos ^a   Vassilakopoulos, Theodoros P ^a   Michalis, Evridiki ^a,b   Roussou, Paraskevi ^a   Vrakidou, Effimia ^c   Repousis, Panayiotis ^d   Angelopoulou, Maria K ^a   Siakantaris, Marina P ^a   Korantzis, John ^e   Symeonidis, Argyrios ^f   Grigorakis, Vassiliki ^b   Stefanoudakis, Ekaterini ^g   Stamatellou, Marina ^h   Bourantas, Konstantinos L ⁱ   Kalmantis, Themis ^a   Christopoulous, George ^j   Kokkinis, Garyfallia ^k   Mihalakeas, Ilias ^l   Papayiannis, Antonios ^c  

^a UNIVERSITY OF ATHENS   (Greece)

^b KAT HOSPITAL   (Greece)

^c HYGEIA HOSPITAL   (Greece)

^d Anticancer Hospital   (Greece)

^e THEAGENIO CANCER HOSPITAL   (Greece)

^f UNIVERSITY OF PATRAS   (Greece)

^g AMALIA FLEMING GENERAL HOSPITAL   (Greece)

^h O Aghios Savas Hospital   (Greece)

ⁱ UNIVERSITY OF IOANNINA   (Greece)

^j First Dept of Internal Medicine   (Greece)

^k Sismanoglian Hospital   (Greece)

^l 401 Army Hospital   (Greece)

more..

Author keywords

Advanced; Aggressive; CHOP; CNOP; Non Hodgkin's lymphoma

Indexed keywords

ALPHA INTERFERON; ANTHRAQUINONE DERIVATIVE; CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; PREDNISONE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FEVER; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LEUKOPENIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOCYTIC, ACUTE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MITOXANTRONE; PREDNISOLONE; PREDNISONE; PROGNOSIS; TIME FACTORS; TREATMENT OUTCOME; VINCRISTINE;

EID: 0037375865     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819031000063471     Document Type: Article

References (57)

1. McKelvey, E.M., Gottlieb, J.A., Wilson, H.E., Haut, A., Talley, R.W., Stephens, R., Lane, M., Gamble, J.F., Jones, S.E., Grozea, P.N., Gutterman, J., Coltman, C. and Moon, T.E. (1976) "Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma", Cancer 38, 1484-1493.
2. Hagberg, H., Bjorkholm, M., Glimelius, B., Lindemalm, C., Mellstedt, H. and Killander, A. (1985) "CHOP versus MEV for the treatment of non-Hodgkin's lymphoma of unfavourable histopathology: a randomized clinical trial", European Journal of Cancer Clinical Oncology 21, 175-179.
3. Wolf, M., Matthews, J.P., Stone, J., Cooper, I.A., Robertson, T.I. and Fox, R.M. (1997) "Long-term survival advantage of MACOP-B over CHOP in intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group", Annals of Oncology 8(Suppl. 1), 71-75.
4. Gordon, L.I., Harrington, D., Andersen, J., Colgan, J., Glick, J., Neiman, R., Mann, R., Resnick, G.D., Barcos, M., Gottlieb, A. and O' Connell, M. (1992) "Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma", New England Journal of Medicine 327, 1342-1349.
5. Klimo, P. and Connors, J.M. (1985) "MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma", Annals of Internal Medicine 102, 596-602.
6. Miller, T.P., Dahlberg, S., Weick, J.K., Files, J.C., Eyre, H.J., Pendergrass, K.B. and Fisher, R.I. (1990) "Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study", Journal of Clinical Oncology 8, 1951-1958.
7. Canellos, G.P., Skarin, A.T., Klatt, M.M., Rosenthal, D.S., Case, Jr., D.C., Pinkus, G.S., Jochelson, M.S., Yeap, B.Y. and Shipp, M.A. (1987) "The m-BACOD combination chemotherapy regimen in the treatment of diffuse large cell lymphoma", Seminars in Hematology 24(Suppl. 1), 2-7.
8. Longo, D.L., De Vita, Jr., V.T., Duffey, P.L., Wesley, M.N., Ihde, D.C., Hubbard, S.M., Gilliom, M., Jaffe, E.S., Cossman, J. and Fisher, R.I. (1991) "Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial", Journal of Clinical Oncology 9, 25-38.
9. Fisher, R.I., Gaynor, E.R., Dahlberg, S., Oken, M.M., Grogan, T.M., Mize, E.M., Glick, J.H., Coltman, Jr., C.A. and Miller, T.P. (1993) "Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma", New England Journal of Medicine 328, 1002-1006.
10. The International non-Hodgkin's Lymphoma Prognostic Factors Project (1993) "A predictive model for aggressive non-Hodgkin's lymphoma", New England Journal of Medicine 329, 987-994.
11. Shipp, M.A., Neuberg, D., Janicek, M., Canellos, G.P. and Shulman, L.N. (1995) "High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study", Journal of Clinical Oncology 13, 2916-2923.
12. Coltman, Jr., C.A., Coltman, T.M., Balcerzak, S.P., Morrison, F.S. and Von Hoff, D.D. (1984) "Mitoxantrone in refractory non Hodgkin's lymphoma. A Southwest Oncology Group study", Seminars in Oncology 11(3 Suppl. 1), 50-53.
13. Silver, R.T., Case, Jr., D.C., Wheeler, R.H., Miller, T.P., Stein, R.S., Stuart, J.J., Peterson, B.A., Rivkin, S.E., Golomb, H.M., Costanzi, J.J., Erslev, A.J., Reisman, A. and Dugan, M. (1991) "Multicenter clinical trial of mitoxantrone in non-Hodgkin's lymphoma and Hodgkin's disease", Journal of Clinical Oncology 9, 754-761.
14. Angelopoulou, M.K., Lafioniatis, S.N. and Pangalis, G.A. (1994) "Low grade non-Hodgkin's lymphomas: disease control with mitoxanthrone monotherapy in patients refractory to conventional therapy", Leukemia and Lymphoma 12, 253-257.
15. Gaynor, E.R., Dahlberg, S. and Fisher, R.I. (1994) "Factors affecting reduced survival of the elderly with intermediate and high grade lymphoma: an analysis of SWOG 8516 (Int 0067)-the national high priority lymphoma study-a randomized comparison of CHOP vs m-BACOD vs ProMACE-CytaBOM vs MACOP-B", Proceedings of American Society of Clinical Oncology 13, 370.
16. Gherlinzoni, F., Guglielmi, C., Mazza, P., Amadori, S., Mandelli, F. and Tura, S. (1990) "Phase III comparative trial (m-BACOD, v m-BNCOD) in the treatment of stage II to IV non-Hodgkin's lymphomas with intermediate- or high-grade histology", Seminars in Oncology 17(6 Suppl. 10), 3-9.
17. Sonneveld, P. and Michiels, J.J. (1990) "Full dose chemotherapy in elderly patients with non-Hodgkin's lymphoma: a feasibility study using a mitoxantrone containing regimen", British Journal of Cancer 61, 105-108.
18. Ho, A., Del Valle, F., Ruckle, H., Schwammborn, J., Schlimok, G., Hiddemann, W., Meusers, P., Thiel, E., Dorken, B. and Hunstein, W. (1989) "Mitoxantrone and high-dose cytarabine as salvage therapy for refractory non-Hodgkin's lymphoma", Cancer 64, 1388-1392.
19. Brusamolino, E., Bertini, M., Guidi, S., Vitolo, U., Inverardi, D., Merante, S., Colombo, A., Resegotti, L., Bernasconi, C., Ferrini, P.R., Cametti, G. and Canta, M. (1988) "CHOP versus CNOP (N = Mitoxantrone) in non-Hodgkin's lymphoma: an interim report comparing efficacy and toxicity", Haematologica 73, 217-222.
20. Saletan, S.L. (1987) Mitoxantrone: Cardiotoxicity. Abstract of the first Nordic Novantrone Symposium, Stockholm, 34-35.
21. Bennett, J.M., Muss, H.B., Doroshow, J.H., Wolff, S., Krementz, E.T., Cartwright, K., Dukart, G., Reisman, A. and Schoch, I. (1988) "A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma", Journal of Clinical Oncology 6, 1611-1620.
22. Posner, L.E., Dukart, G., Goldberg, J., Bernstein, T. and Cartwright, K. (1985) "Mitoxantrone: An overview of safety and toxicity", Investigational New Drugs 3, 123-132.
23. Bezwoda, W., Rastogi, R.B., Erazo Valla, A., Diaz-Maqueo, J.C., Pavlovsky, S., Morioka, H., Resegotti, L., Rueckle, H., Somoza, N., Moreno-Nogueira, J.A., Bernasconi, C., Ho, A., Burns, I., Lardinois, J., van der Merwe, A., Richards, E. and the Novantrone International Study Group (1995) "Long-term results of a multicentre randomized, comparative phase III trial of CHOP versus CNOP regimens in patients with intermediate- and high-grade non-Hodgkin's lymphomas", European Journal of Cancer 31, 903-911.
24. Sonneveld, P., de Ridder, M., van der Lelie, H., Nieuwenhuis, K., Schouten, H., Mulder, A., van Reijswoud, I. and Lowenberg, B. (1995) "Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy", Journal of Clinical Oncology 13, 2530-2539.
25. Kimura, I., Ohnoshi, T., Masaoka, T., Sampi, K. and Namba, K. (1986) "A comparative study of mitoxantrone and adriamycin in patients with non-Hodgkin's lymphoma: a preliminary result", Gan To Kagaku Ryoho-Japanese Journal of Cancer Chemotherapy 13, 2813-2819.
26. Chuang, M.W., Tzeng, C.H., Chiou, T.J., Chiu, C.F., Hsieh, R.K., Liu, J.H. and Chen, P.M. (1988) "A comparative trial of C-novantrone-OP (CNOP) vs C-adriamycin-OP (CHOP) in the treatment of stage II-IV malignant lymphoma-the preliminary report", Zhonghua Yi Xue Za Zhi (Taipei) 41, 51-56.
27. Economopoulos, T., Dimopoulos, M.A., Mellou, S., Pavlidis, S., Samantas, E., Nicolaides, C., Tsatalas, C., Papadopoulos, A., Papageorgiou, E., Papasavvas, P. and Fountzilas, G. (2002) "Treatment of intermediate and high grade non-Hodgkin's lymphoma using CEOP versus CNOP", European Journal of Haematology 68, 135-143.
28. Guglielmi, C., Gherlinzoni, F., Amadori, S., Mazza, P., Mantovani, L., Lauria, F., Martelli, M., Zinzani, P.L., Greco, V., Poletti, G., Gherardi, S., Mandelli, F. and Tura, S. (1989) "A phase III comparative trial of m-BACOD vs m-BNCOD, in the treatment of stage II-IV diffuse non-Hodgkin's lymphomas", Haematologica 74, 563-569.
29. Mainwaring, P.N., Cunningham, D., Gregory, W., Hoskin, P., Hancock, B., Norton, A.J., MacLennan, K., Smith, P., Hudson, G.V. and Linch, D. (2001) "Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEB0 versus PMitCEBO", Blood 97, 2991-2997.
30. Zinzani, P.L., Storti, S., Zaccaria, A., Moretti, L. , Magagnoli, M., Pavone, E., Gentilini, P., Guardigni, L., Gobbi, M., Fattori, P.P., Falini, B., Lauta, V.M., Bendandi, M., Gherlinzoni, F., De Renzo, A., Zaja, F., Mazza, P., Volpe, E., Bocchia, M., Aitini, E., Tabanelli, M., Leone, G. and Tura, S. (1999) "Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients", Blood 94, 33-38.
31. The Non-Hodgkin's Lymphoma Pathologic Classification Project (1982) "National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and a description of a working formulation for clinical usage", Cancer 49, 2112-2135.
32. Carbone, P.P., Kaplan, H.S., Musshof, K., Smithers, D.W. and Tubiana, M. (1971) "Report on the Committee on Hodgkin's disease staging classification", Cancer Research 3, 1860-1861.
33. Gottlieb, J.A., Gutterman, J.A., McCredie, K.B., Rodriguez, V. and Frei, 3rd, E. (1973) "Chemotherapy of malignant lymphoma with adriamycin", Cancer Research 33, 3024-3028.
34. Hryniuk, W.M. and Goodyear, M. (1990) "The calculation of received dose intensity", Journal of Clinical Oncology 8, 1935-1937.
35. Lepage, E., Gisselbrecht, C., Haioun, C., Sebban, C., Tilly, H., Bosly, A., Morel, P., Herbrecht, R., Reyes, F. and Coiffier, B. (1993) "Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol", Annals of Oncology 4, 651-656.
36. Miller, A.B., Hoogstraten, B., Staquet, M. and Winkler, A. (1981) "Reporting results in cancer treatment", Cancer 47, 207-214.
37. Armitage, P. and Berry, G. (1987) Statistical methods in medical research, 2nd Ed. (Blackwell Scientific Publications, Oxford, England).
38. Kaplan, E. and Meier, P. (1958) "Non-parametric estimation from incomplete observations", Journal of American Statistical Association 53, 457-481.
39. Mantel, N. (1966) "Evaluation of survival data and two new rank order statistics arising in its consideration", Cancer Chemotherapy Reports 50, 163-170.
40. Cox, D.R. (1972) "Regression models and life tables", Journal of Royal Statistical Society 34, 187-220.
41. Giles, F.J., Shan, J., Advani, S.H., Akan, H., Aydogdu, I., Aziz, Z., Azim, H.A., Bapsy, P.P., Buyukkececi, F., Chaimongkol, B., Chen, P.M., Cheong, S.K., Ferhanoglu, B., Hamza, R., Khalid, H.M., Intragumtornchai, T., Kim, S.W., Kim, S.Y., Koc, H., Kumar, L., Kumar, R., Lei, K.I., Lekhakula, A., Muthalib, A., Patel, M., Poovalingam, V.P., Prayoonwiwat, W., Rana, F., Reksodiputro, A.H., Ruff, P., Sagar, T.G., Schwarer, A.P., Song, H.S., Suh, C.W., Suharti, C., Supindiman, I., Tee, G.Y., Thamprasit, T., Villalon, A.H., Wickham, N.R., Wong, J.E., Yalcin, A., Jootar, S. and the International Oncology Study Group NHL1 Study (2000) "A prospective randomized study of CHOP versus CHOP plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: the International Oncology Study Group NHL1 Study", Leukemia and Lymphoma 40, 95-103.
42. Aviles, A., Cleto, S., Huerta-Guzman, J. and Neri, N. (2001) "Interferon alfa 2b as maintenance therapy in poor risk diffuse large B-cell lymphoma in complete remission after intensive CHOP-BLEO regimens", European Journal of Haematology 66, 94-99.
43. Gribabis, D.A., Vassilakopoulos, T.P., Boussiotis, V.A., Kontopidou, F., Kittas, Ch., Fessas, Ph. and Pangalis, G.A. (1996) "Salvage therapy of non-Hodgkin's lymphoma with mitoxantrone, etoposide, vinblastine, bleomycin and prednisone (NVVBP) combination", British Journal of Haematology 93(Suppl. 2), 369.
44. Linassier, C., Barin, C., Calais, G., Letortorec, S., Bremond, J.-L., Delain, M., Petit, A., Georget, M.-T., Cartron, G., Raban, N., Benboubker, L., Leloup, R., Binet, C., Lamagnere, J.-P. and Colombat, P. (2000) "Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy", Annals of Oncology 11, 1289-1294.
45. Hossfeld, D.K. (2000) "Mitoxantrone-related acute myelocytic leukemias", Annals of Oncology 11, 1215-1216.
46. Chaplain, G., Milan, C., Sgro, C., Carli, P.M. and Bonithon-Kopp, C. (2000) "Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: a population-based study", Journal of Clinical Oncology 18, 2836-2842.
47. Santoro, A., Balzarotti, M., Tondini, C., Zanini, M., Giardini, R., Latteri, F., Rampinelli, I. and Bufalino, R. (1999) "Dose-escalation of CHOP in non-Hodgkin's lymphoma", Annals of Oncology 10, 519-525.
48. Itoh, K., Ohtsu, T., Wakita, H., Igarashi, T., Ishizawa, K., Onozawa, Y., Fujii, H., Minami, H. and Sasaki, Y. (2000) "Dose-escalation study of CHOP with or without prophylactic G-CSF in aggressive non-Hodgkin's lymphoma", Annals of Oncology 11, 1241-1247.
49. Bartlett, N.L., Petroni, G.R., Parker, B.A., Wagner, N.D., Gockerman, J.P., Omura, G.A., Canellos, G.P., Cooper, M.R., Johnson, J.L. and Peterson, B.A. (2001) "Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma", Cancer 92, 207-217.
50. Pfreundschuh, M., Trumper, L., Kloess, M., Schmitz, N., Glass, B., Schmits, R., Engert, A., Rudolph, C., Illiger, J., Hossfeld, D. and Loeffler, M. (2002) "CHOEP (CHOP + Etoposide) is the new standard regimen for young patients with low-risk (low LDH) aggressive non-Hodgkin's lymphoma", Annals of Oncology 13(Suppl. 2), 74.
51. Haioun, C., Lepage, E., Gisselbrecht, C., Salles, G., Coiffier, B., Brice, P., Bosly, A., Morel, P., Nouvel, C., Tilly, E., Lederlin, P., Sebban, C., Briere, J., Gaulard, P. and Reyes, F. (2000) "Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol-a Groupe d' Etude des Lymphomes de l' Adulte study", Journal of Clinical Oncology 18, 3025-3030.
52. Mounier, N., Haioun, C., Cole, B.F., Gisselbrecht, C., Sebban, C., Morel, P., Marit, G., Bouabdallah, R., Ravoet, C., Salles, G., Reyes, F. and Lepage, E. (2000) "Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'Etude les Lymphomes de l' Adulte (GELA)", Blood 95, 3687-3692.
53. Milpied, N., Deconninck, E., Colombat, Ph., Ifrah, N., Delwail, V., Berthou, C., Gressin, R., Lamy, T., Jaubert, J., Casassus, Ph., Le Maignan, C., Maisonneuve, H., Ramee, J.F., Lemevel, A., Jardel, H., Desablens, B. and Harousseau, J.L. (2002) "Frontline high-dose chemotherapy with autologous stem cell transplantation vs standard CHOP regimen for patients (≤60 yo) with non-IPI high-risk intermediate or high grade lymphomas. Final results of a randomised trial by GOELAMS", Annals of Oncology 13 (Suppl. 2), 28.
54. Linch, D.C., Yung, L., Smith, P., Maclennan, K., Jack, A., Hancock, B., Cunningham, D., Hoskin, P., Holte, H., Boesen, A.M., Grigg, A. and Browett, P. (2002) "A randomised trial of CHOPx6-8 vs CHOPx3 + BEAM + ASCT in 457 patients with poor prognosis histologically aggressive non-Hodgkin's lymphoma", Annals of Oncology 13(Suppl. 2), 28.
55. Vitolo, U., Liberati, A.M., Lambertenghi Deliliers, G., Calvi, R., Baldini, L., Bertini, M., Boccomini, C., Brugiatelli, M., Cabras, M.G., Di Renzo, N., Federico, M., Freilone, M., Levis, A., Parvis, G., Pavone, E., Pregno, P., Petrini, P., Sborgia, M., Todeschini, G., Trottini, M. and Gallo, E. (2002) "High dose chemotherapy with autologous stem cell transplantation vs intensified chemotherapy MegaCEOP in high risk diffuse large cell lymphoma: An update of a multicenter randomized trial by Italian Lymphoma Intergroup", Annals of Oncology 13(Suppl. 2), 29.
56. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., van den Neste, E., Salles, G., Gaulard, P., Reyes, F. and Gisselbrecht, C. (2002) "CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma", New England Journal of Medicine 346, 235-242.
57. Pfreundschuh, M., Trumper, L., Kloess, M., Schmitz, N., Glass, B., Schmits, R., Engert, A., Rudolph, C., Illiger, J., Hossfeld, D. and Loeffler, M. (2002) "2-weekly CHOP (CHOP-14.): the new standard regimen for patients with aggressive non-Hodgkin's lymphoma >60 years of age", Annals of Oncology 13(Suppl. 2), 27.